Advertisement

Current Cardiology Reports

, 20:130 | Cite as

Challenges in Aortic Stenosis: Review of Antiplatelet/Anticoagulant Therapy Management with Transcatheter Aortic Valve Replacement (TAVR): TAVR with Recent PCI, TAVR in the Patient with Atrial Fibrillation, and TAVR Thrombosis Management

  • Matthew W. Sherwood
  • Amit N. Vora
Valvular Heart Disease (TL Kiefer, Section Editor)
  • 9 Downloads
Part of the following topical collections:
  1. Topical Collection on Valvular Heart Disease

Abstract

Purpose of Review

This review aims to describe the current evidence and consensus recommendations around antiplatelet and anticoagulant management in three common clinical scenarios in transcatheter aortic valve replacement (TAVR): (1) recent percutaneous coronary intervention (PCI) preceding TAVR, (2) atrial fibrillation (AF) management in patients undergoing TAVR, and (3) bioprosthetic valve thrombosis management in TAVR.

Recent Findings

Several small clinical trials have evaluated the use of single vs. dual antiplatelet therapy in patients undergoing TAVR, with most recent data favoring single antiplatelet therapy. There are several trials currently enrolling and in follow-up that evaluate the use of anticoagulants in combination with single and dual antiplatelet therapy for patients with AF undergoing TAVR, but as yet, there is no data to support a clear strategy. The use of DAPT after PCI continues to potentially shorten in patients undergoing elective PCI, thus prolonged DAPT may not be necessary post TAVR for the sake of PCI. Bioprosthetic valve thrombosis occurs more commonly than previously thought, but has uncertain clinical significance. In observational studies, antiplatelet therapy has little effect on bioprosthetic valve thrombosis, whereas anticoagulation is effective in both prevention and treatment of thrombosis.

Summary

DAPT is currently recommended for 1–6 months for all patients without an indication for oral anticoagulation who undergo TAVR; however, there is a growing amount of evidence for single antiplatelet therapy. In the special situation of patients who have recently undergone PCI, the length of DAPT will depend on stent selection (BMS vs. DES), but may not be significantly prolonged unless the patient experienced an acute coronary syndrome prior to TAVR. There is no clear, optimal antithrombotic strategy for patients with AF who undergo TAVR, but avoidance of triple therapy by using OAC and low-dose ASA seems to be reasonable. OAC, not DAPT, is now known to prevent bioprosthetic valve thrombosis in TAVR and SAVR patients; however, the optimal therapy remains unknown. For patients who develop bioprosthetic valve thrombosis, OAC for 3–6 months, and repeat imaging is recommended to document resolution.

Keywords

TAVR Aortic stenosis Atrial fibrillation PCI Thrombosis 

Notes

Compliance with Ethical Standards

Conflict of Interest

Matthew W. Sherwood reports honoraria/consulting fees from Janssen, and honoraria from Medtronic.

Amit N. Vora declares no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.CrossRefGoogle Scholar
  2. 2.
    Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609–20.CrossRefGoogle Scholar
  3. 3.
    Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321–31.CrossRefGoogle Scholar
  4. 4.
    Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187–98.CrossRefGoogle Scholar
  5. 5.
    Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–8.CrossRefGoogle Scholar
  6. 6.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2438–88.CrossRefGoogle Scholar
  7. 7.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;70:252–89.CrossRefGoogle Scholar
  8. 8.
    Chopard R, Teiger E, Meneveau N, Chocron S, Gilard M, Laskar M, et al. Baseline characteristics and prognostic implications of pre-existing and new-onset atrial fibrillation after transcatheter aortic valve implantation: results from the FRANCE-2 registry. JACC Cardiovasc Interv. 2015;8:1346–55.CrossRefGoogle Scholar
  9. 9.
    Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, de Backer O, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–24.CrossRefGoogle Scholar
  10. 10.
    Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383–92.CrossRefGoogle Scholar
  11. 11.
    Sherwood MW, Vemulapalli S, Harrison JK, Dai D, Vora AN, Mack MJ, et al. Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: insights from the STS/ACC TVT registry. Am Heart J. 2018;204:9–16.CrossRefGoogle Scholar
  12. 12.
    Aryal MR, Karmacharya P, Pandit A, Hakim F, Pathak R, Mainali NR, et al. Dual versus single antiplatelet therapy in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Heart Lung Circ. 2015;24:185–92.CrossRefGoogle Scholar
  13. 13.
    Gandhi S, Schwalm JD, Velianou JL, Natarajan MK, Farkouh ME. Comparison of dual-antiplatelet therapy to mono-antiplatelet therapy after transcatheter aortic valve implantation: systematic review and meta-analysis. Can J Cardiol. 2015;31:775–84.CrossRefGoogle Scholar
  14. 14.
    •• Rodes-Cabau J, Masson JB, Welsh RC, et al. Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovasc Interv. 2017;10(13):1357–65.  https://doi.org/10.1016/j.jcin.2017.04.014 This study is the largest randomized controlled trial of antiplatelet therapy after TAVR. Although underpowered, it showed that patients on aspirin monotherapy had similar rates of stroke/MI/death and much lower rates of major bleeding compared with patients given dual antiplatelet therapy. CrossRefPubMedGoogle Scholar
  15. 15.
    Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014;174:624–7.CrossRefGoogle Scholar
  16. 16.
    Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011;108:1772–6.CrossRefGoogle Scholar
  17. 17.
    Kotronias RA, Kwok CS, George S, Capodanno D, Ludman PF, Townend JN, et al. Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6.Google Scholar
  18. 18.
    Van Mieghem NM, van der Boon RM, Faqiri E, et al. Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice. JACC Cardiovasc Interv. 2013;6:867–75.CrossRefGoogle Scholar
  19. 19.
    Chakravarty T, Sharma R, Abramowitz Y, Kapadia S, Latib A, Jilaihawi H, et al. Outcomes in patients with transcatheter aortic valve replacement and left main stenting: the TAVR-LM registry. J Am Coll Cardiol. 2016;67:951–60.CrossRefGoogle Scholar
  20. 20.
    Bajaj A, Pancholy S, Sethi A, Rathor P. Safety and feasibility of PCI in patients undergoing TAVR: a systematic review and meta-analysis. Heart & lung : the J Critical Care. 2017;46:92–9.CrossRefGoogle Scholar
  21. 21.
    • Ramee S, Anwaruddin S, Kumar G, et al. The rationale for performance of coronary angiography and stenting before transcatheter aortic valve replacement: from the Interventional Section Leadership Council of the American College of Cardiology. JACC Cardiovasc Interv. 2016;9:2371–5 This manuscript is a consensus statement on the utility of percutaneous coronary intervention in patients undergoing TAVR. There is no definitive evidence on the optimal strategy for PCI in TAVR, but provides a framework for this decision. CrossRefGoogle Scholar
  22. 22.
    Schulz-Schupke S, Byrne RA, Ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252–63.CrossRefGoogle Scholar
  23. 23.
    Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA : the journal of the American Medical Association. 2013;310:2510–22.PubMedGoogle Scholar
  24. 24.
    Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017;38:1034–43.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155–66.CrossRefGoogle Scholar
  26. 26.
    Bittl JA, Baber U, Bradley SM, Wijeysundera DN. Duration of dual antiplatelet therapy: a systematic review for the 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016;134:e156–78.PubMedGoogle Scholar
  27. 27.
    Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68:1082–115.CrossRefGoogle Scholar
  28. 28.
    Kolh P, Windecker S. ESC/EACTS myocardial revascularization guidelines 2014. Eur Heart J. 2014;35:3235–6.CrossRefGoogle Scholar
  29. 29.
    Khawaja MZ, Wang D, Pocock S, Redwood SR, Thomas MR. The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial. Trials. 2014;15:300.CrossRefGoogle Scholar
  30. 30.
    Holmes DR Jr, Brennan JM, Rumsfeld JS, et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA :J Am Med Assoc. 2015;313:1019–28.CrossRefGoogle Scholar
  31. 31.
    Tarantini G, Mojoli M, Urena M, Vahanian A. Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. Eur Heart J 2016, ehw456.Google Scholar
  32. 32.
    Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, Heimansohn D, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol. 2014;63:1972–81.CrossRefGoogle Scholar
  33. 33.
    Tanawuttiwat T, O'Neill BP, Cohen MG, Chinthakanan O, Heldman AW, Martinez CA, et al. New-onset atrial fibrillation after aortic valve replacement: comparison of transfemoral, transapical, transaortic, and surgical approaches. J Am Coll Cardiol. 2014;63:1510–9.CrossRefGoogle Scholar
  34. 34.
    Tarantini G, Mojoli M, Windecker S, Wendler O, Lefèvre T, Saia F, et al. Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry. JACC Cardiovasc Interv. 2016;9:937–46.CrossRefGoogle Scholar
  35. 35.
    Urena M, Hayek S, Cheema AN, Serra V, Amat-Santos IJ, Nombela-Franco L, et al. Arrhythmia burden in elderly patients with severe aortic stenosis as determined by continuous electrocardiographic recording: toward a better understanding of arrhythmic events after transcatheter aortic valve replacement. Circulation. 2015;131:469–77.CrossRefGoogle Scholar
  36. 36.
    Vora AN, Dai D, Matsuoka R, Harrison JK, Hughes GC IV, Sherwood MW, et al. Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement: an analysis from the STS/ACC TVT registry. JACC Cardiovasc Interv. 2018;11:1746–56.CrossRefGoogle Scholar
  37. 37.
    Nijenhuis VJ, Bennaghmouch N, Hassell M, Baan J Jr, van Kuijk JP, Agostoni P, et al. Rationale and design of POPular-TAVI: antiPlatelet therapy for patients undergoing transcatheter aortic valve implantation. Am Heart J. 2016;173:77–85.CrossRefGoogle Scholar
  38. 38.
    Egbe AC, Pislaru SV, Pellikka PA, Poterucha JT, Schaff HV, Maleszewski JJ, et al. Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors. J Am Coll Cardiol. 2015;66:2285–94.CrossRefGoogle Scholar
  39. 39.
    Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol. 2012;60:971–7.CrossRefGoogle Scholar
  40. 40.
    Abdul-Jawad Altisent O, Durand E, Munoz-Garcia AJ, et al. Warfarin and antiplatelet therapy versus warfarin alone for treating patients with atrial fibrillation undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2016;9:1706–17.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Inova Heart and Vascular InstituteFalls ChurchUSA
  2. 2.Duke Clinical Research InstituteDurhamUSA

Personalised recommendations